Viking Global Investors LP Biomarin Pharmaceutical Inc Transaction History

Viking Global Investors LP

$25.8 Billion
Q3 2024

A detailed history of Viking Global Investors LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Viking Global Investors LP holds 9,753,293 shares of BMRN stock, worth $619 Million. This represents 2.65% of its overall portfolio holdings.

Number of Shares

9,753,293

Previous 7,063,564 38.08%

Holding current value

$619 Million

Previous $582 Million 17.89%

% of portfolio

2.65%

Previous 2.31%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $186 Million - $252 Million	2,689,729 Added 38.08%	9,753,293 $686 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $48.2 Million - $59.7 Million	647,276 Added 10.09%	7,063,564 $582 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $128 Million - $151 Million	1,526,834 Added 31.23%	6,416,288 $560 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $51.4 Million - $66.4 Million	673,998 Added 15.99%	4,889,454 $471 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $4.99 Million - $5.54 Million	58,671 Added 1.41%	4,215,456 $373 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $172 Million - $199 Million	1,988,168 Added 91.68%	4,156,785 $360 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $272 Million - $364 Million	-3,105,003 Reduced 58.88%	2,168,617 $211 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $14.1 Million - $19 Million	174,456 Added 3.42%	5,273,620 $546 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $3.83 Million - $4.51 Million	46,571 Added 0.92%	5,099,164 $432 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $92.9 Million - $113 Million	1,300,200 Added 34.65%	5,052,593 $419 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $65.5 Million - $81.8 Million	882,446 Added 30.75%	3,752,393 $289 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $206 Million - $263 Million	2,869,947 New	2,869,947 $254 Million
Q2 2020 Aug 07, 2020	SELL	$79.55 - $124.22 $116 Million - $181 Million	-1,453,625 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $12 Million - $16.3 Million	-168,114 Reduced 10.37%	1,453,625 $123 Million
Q4 2019 Feb 13, 2020	SELL	$64.27 - $86.37 $92.3 Million - $124 Million	-1,436,365 Reduced 46.97%	1,621,739 $137 Million
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $31.5 Million - $39.8 Million	467,753 Added 18.06%	3,058,104 $206 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $204 Million - $238 Million	-2,538,558 Reduced 49.5%	2,590,351 $222 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $3.14 Million - $3.68 Million	37,272 Added 0.73%	5,128,909 $456 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $77.2 Million - $102 Million	962,696 Added 23.32%	5,091,637 $434 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $81.6 Million - $91.9 Million	869,184 Added 26.66%	4,128,941 $400 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $120 Million - $156 Million	1,577,291 Added 93.75%	3,259,757 $307 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $131 Million - $156 Million	1,682,466 New	1,682,466 $136 Million
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $20.9 Million - $24.7 Million	-259,656 Closed	0 $0
Q2 2017 Aug 14, 2017	SELL	N/A	-616,457 Reduced 70.36%	259,656 $23.6 Million
Q1 2017 May 15, 2017	SELL	N/A	-522,344 Reduced 37.35%	876,113 $76.9 Million
Q4 2016 Feb 14, 2017	BUY	N/A	908,153 Added 185.22%	1,398,457 $116 Million
Q3 2016 Nov 14, 2016	BUY	N/A	490,304 New	490,304 $45.4 Million
Q2 2016 Aug 15, 2016	SELL	N/A	-602,116 Closed	0 $0
Q1 2016 May 16, 2016	BUY	N/A	602,116	602,116 $49.7 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Viking Global Investors LP with notifications on news.

Account

Viking Global Investors LP Biomarin Pharmaceutical Inc Transaction History